Back to Journals » OncoTargets and Therapy » Volume 6

Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers

Total article views   HTML views PDF downloads Totals
20,437 Dovepress* 14,586+ 3,537 18,123
PubMed Central* 5,851 1,942 7,793
Totals 20,437 5,479 25,916
*Since 5 November 2013
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
5 0 0 0 0 5

View citations on PubMed Central and Google Scholar